DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT)
Clinical trials for DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) explained in plain language.
Never miss a new study
Get alerted when new DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) trials appear
Sign up with your email to follow new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control NO_LONGER_AVAILABLEThis expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Matched conditions: DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT)
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail targets rare tumor in kids
Disease control OngoingThis early-phase trial adds three drugs—irinotecan, temozolomide, and bevacizumab—to the usual chemotherapy for newly diagnosed desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. The study includes 15 patients aged 1 to 30 and aims to see if the combinatio…
Matched conditions: DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT)
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC